A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of Adalimumab in children with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 8, 2011, Pages 946-953

  Russell, R K ^a   Wilson, M L ^b   Loganathan, S ^c,j   Bourke, B ^d   Kiparissi, F ^e   Mahdi, G ^c,f   Torrente, F ^g   Rodrigues, A ^h   Davies, I ⁱ   Thomas, A ^j   Akobeng, A K ^j   Fagbemi, A ^j   Hyer, W ^k   Spray, C ^l   Vaish, S ^d   Rogers, P ^m   McGrogan, P ^a   Heuschkel, R B ^g   Ayub, N ⁿ   Fell, J M ^o   Afzal, N A ^p   Green, M ^q   Murphy, M S ^r   Rao, P ^s   Shah, N ^e   Ho, G T ^t   Naik, S ^u   Wilson, D C ^a,l   more..

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ROYAL ABERDEEN CHILDREN S HOSPITAL   (United Kingdom)

^d OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f DALHOUSIE UNIVERSITY   (Canada)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^j ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^k ST MARK S HOSPITAL   (United Kingdom)

^l BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^m ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

ⁿ ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^o CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^p UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^q LEICESTER ROYAL INFIRMARY   (United Kingdom)

^r UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^s LEEDS GENERAL INFIRMARY   (United Kingdom)

^t WESTERN GENERAL HOSPITAL   (United Kingdom)

^u School of Medicine and Dentistry   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ABDOMINAL ABSCESS; ADOLESCENT; ARTHRITIS; ARTICLE; BLEEDING; CHILD; CHILDHOOD MORTALITY; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CROHN DISEASE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; FATIGUE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE PAIN; IRELAND; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; PAIN; PARENTERAL NUTRITION; PARONYCHIA; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; REMISSION; SCORING SYSTEM; SEPSIS; ULCERATIVE COLITIS; UNITED KINGDOM; VIRAL RESPIRATORY TRACT INFECTION; VISUAL IMPAIRMENT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HEALTH SURVEYS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRELAND; MALE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952803048     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04603.x     Document Type: Article

References (48)

1. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van LJ, Griffiths AM,. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-39.
2. Armitage E, Drummond H, Ghosh S, Ferguson A,. Incidence of juvenile-onset Crohn's disease in Scotland. Lancet 1999; 353: 1496-7. (Pubitemid 29204375)
3. Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001; 357: 1093-4. (Pubitemid 32322542)
4. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
5. Akobeng A,. Crohn's disease: current treatment options. Arch Dis Child 2008; 93: 787-92.
6. Wilson D, Thomas A, Croft N, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2010; 50 (Suppl. 1): S14-34.
7. Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H,. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50 (Suppl. 1): S1-13.
8. Mossop H, Davies P, Murphy MS,. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2008; 47: 123-9.
9. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007; 102: 2804-12. (Pubitemid 350179322)
10. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73. (Pubitemid 46454266)
11. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
12. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn's disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52: 31-7.
13. Walters TD, Gilman AR, Griffiths AM,. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13: 424-30. (Pubitemid 46668247)
14. Bultman E, Kuipers EJ, Van Der Woude CJ,. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32: 313-23.
15. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
16. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
17. Peyrin-Biroulet L, Laclotte C, Bigard MA,. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007; 25: 675-80.
18. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008; 27: 308-15.
19. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 409-18. (Pubitemid 46184454)
20. Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009; 104: 3042-9.
21. Veres G, Putz R, Szabo D, et al. Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease. Orv Hetil 2009; 150: 1858-60.
22. Nguyen KDK, Alexis R, Schwarz SM,. Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease. J Pediatr Gastroenterol Nutr 2010; 50: 225-6.
23. Mian S, Baron H,. Adalimumab, a novel anti-tumor necrosis factor-[alpha] antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005; 41: 357-9. (Pubitemid 41285833)
24. Hadziselimovic F,. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. J Pediatr Gastroenterol Nutr 2008; 46: 208-11. (Pubitemid 351161129)
25. Viola F, Civitelli F, Di NG, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009; 104: 2566-71.
26. Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L,. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 47: 19-25.
27. Rosenbach Y, Hartman C, Shapiro R, Hirsch A, Avitzur Y, Shamir R,. Adalimumab treatment in children with refractory Crohns disease. Dig Dis Sci 2010; 55: 747-53.
28. Noe JD, Pfefferkorn M,. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1683-7.
29. Lees CW, Ironside J, Wallace WA, Satsangi J,. Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med 2008; 359: 320-1. (Pubitemid 352008468)
30. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41.
31. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M,. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7. (Pubitemid 46175082)
32. Shale M, Kanfer E, Panaccione R, Ghosh S,. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut 2008; 57: 1639-41.
33. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-47.
34. IBD Working Group of the European Society for Paediatric Gastroenterology HaN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-The Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
35. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170: 2-6. (Pubitemid 20015811)
36. Silverberg MS, Satsangi J, Ahmad T, et al. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): 5-36.
37. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 2009; 29: 527-34.
38. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009; 15: 1308-19.
39. Manz M, Beglinger C, Vavricka SR,. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut 2009; 58: 149.
40. Crombé V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in paediatric Crohn's disease: a population-based study. J Crohn's Colitis 2010; 4: S6.
41. Diak P, Siegel J, La GL, Choi L, Lemery S, McMahon A,. Malignancy in children and tumor necrosis factor-alpha blockers: forty-eight cases reported to the food and drug administration. Arthritis Rheum 2010; 62: 2517-24.
42. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31: 1296-309.
43. Oussalah A, Danese S, Peyrin-Biroulet L,. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010; 11: 156-75.
44. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
45. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-8.
46. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
47. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010; 32: 1228-39.
48. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)